Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Olaparib in EGFR+ NSCLC (GOAL)
NCT01513174Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Aug 2011
- Primary completion
- Jul 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started Aug 2011; status: completed.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01513174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513174.